ReviewJournal of neuroinflammation2025
Inflammation in Neuronal Intranuclear Inclusion Disease (NIID): mechanisms, biomarkers, and therapeutic implications.
Review in Journal of neuroinflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Second Pathogenic Protein, PolyGN2C-iso2, Reveals a Dual-Protein Pathology in Neuronal Intranuclear Inclusion Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Immunological characterization of neuronal intranuclear inclusion disease with kidney injury: an exploratory analysis in a multi-center cohort.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuronal intranuclear inclusion disease (NIID) is a group of neurodegenerative diseases caused by GGC repeat expansion and is characterized by diverse clinical manifestations that may characterize a spectrum of underlying pathologies. Extensive inflammatory cell infiltration has been observed in multiple tissues obtained from NIID patients, including the temporal lobe, skin, lungs, colon, kidneys, and fallopian tubes. Intriguingly, eosinophilic intranuclear inclusions have been identified within the nuclei of these infiltrating inflammatory cells, underscoring the central role of inflammation in NIID. The infiltration of immune cells within the brain tissue of NIID patients highlights the critical role of neuroinflammation in disease pathogenesis. Moreover, in patients with NIID, not only is the neutrophil-to-lymphocyte ratio (NLR) markedly elevated but also the peripheral blood cytokine profile substantially altered. Despite the prominent involvement of central and peripheral inflammation in NIID and experimental evidence at the cellular level demonstrating that activation of the NF-κB‒NLRP3 pathway can reduce the burden of intranuclear inclusions and ameliorate phenotypic manifestations, therapeutic strategies targeting inflammation have yet to alter the disease course in human patients. This review presents the latest advancements in the study of inflammatory markers in NIID and the GGC100 cell model. Specifically, it explores the role of inflammatory molecular markers in disease pathogenesis and their correlation with clinical parameters. Furthermore, we summarize the potential applications of certain inflammatory biomarkers as novel therapeutic targets and strategies, which may pave the way for expanded therapeutic interventions in NIID.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.